CX-904 is a conditionally activated T-cell-engaging bispecific designed to target the epidermal growth factor receptor (EGFR) on cancer cells and the CD3 receptor on T cells within the tumor microenvironment. CX-904 uses CytomX’s Probody peptide-masking technology to reduce binding to EGFR and CD3 in normal tissues and direct binding towards tumor tissue.
Purpose: The purpose of this first-in-human study, CTMX-904-101, is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of CX-904 in adult subjects with metastatic or locally advanced unresectable solid tumors.
If you are interested in learning more about this study including participating sites, please visit clinicaltrials.gov.